Canadian Journal of Pain
March 4, 2026
Nandana D. Parakh, Danielle Lessor, Kevin Dang et al.
Although pain experiences differed among participants, all participants reported decreased pain with ketamine infusions. Addressing the stigma associated with ketamine infusions, further research around augmenting durability of ketamine, and providing a safe treatment environment can all improve ketamine's benefit for chronic neuropathic pain. Understanding the barriers and facilitators, as...
Canadian Journal of Pain
November 8, 2024
Jiwon Lee, Kaylyssa Philip, Hance Clarke et al.
3 citations
The PEACE-PAIN trial study design is supported by patient survey responses but may benefit from modifications, namely incorporating thorough discussions of the current evidence for efficacy, safety, tolerability, and approaches to address adverse effects of psilocybin. Additionally, the interest in participation by individuals with prior psychedelic use holds important methodological...
JMIR Research Protocols
April 17, 2024
Akash Goel, Bhavya Kapoor, Hillary Chan et al.
2 citations
Chronic pain affects approximately 8 million Canadians (~20%), impacting their physical and mental health while burdening the health care system with costs of upwards of US $60 billion a year. Indeed, patients are often trialed on numerous medications over several years without reductions to their symptoms. Therefore, there is an urgent need to identify new therapies for chronic pain to improve...
Anesthesiology
October 1, 2023
Akash Goel, Yeshith Rai, Shayan Sivadas et al.
29 citations
Chronic pain is a public health concern that affects approximately 1.5 billion people globally. Conventional therapeutic agents including opioid and non-opioid analgesics have been associated with adverse side effects, issues with addiction, and ineffective analgesia. Novel agents repurposed to treat pain via different mechanisms are needed to fill the therapeutic gap in chronic pain...